메뉴 건너뛰기




Volumn 18, Issue 37, 2012, Pages 5219-5224

Effectiveness of infliximab after adalimumab failure in Crohn's disease

Author keywords

Adalimumab; Biologics; Crohn's disease; Infliximab; Switch

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

EID: 84867753775     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i37.5219     Document Type: Article
Times cited : (31)

References (27)
  • 1
    • 0030451868 scopus 로고    scopus 로고
    • Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)
    • Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-697
    • (1996) Gut , vol.39 , pp. 690-697
    • Shivananda, S.1    Lennard-Jones, J.2    Logan, R.3    Fear, N.4    Price, A.5    Carpenter, L.6    van Blankenstein, M.7
  • 2
    • 34248136340 scopus 로고    scopus 로고
    • Inflammatory bowel disease: Clinical aspects and established and evolving therapies
    • Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657
    • (2007) Lancet , vol.369 , pp. 1641-1657
    • Baumgart, D.C.1    Sandborn, W.J.2
  • 3
    • 0033778364 scopus 로고    scopus 로고
    • Tumor necrosis factor: Biology and therapeutic inhibitors
    • Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-1157
    • (2000) Gastroenterology , vol.119 , pp. 1148-1157
    • Papadakis, K.A.1    Targan, S.R.2
  • 6
    • 0031759492 scopus 로고    scopus 로고
    • Advances in the management of Crohn's disease: Economic and clinical potential of infliximab
    • Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998; 20: 1009-1028
    • (1998) Clin Ther , vol.20 , pp. 1009-1028
    • Hanauer, S.B.1    Cohen, R.D.2    Becker, R.V.3    Larson, L.R.4    Vreeland, M.G.5
  • 8
    • 62049083383 scopus 로고    scopus 로고
    • Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
    • Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-767
    • (2009) Am J Gastroenterol , vol.104 , pp. 760-767
    • Gisbert, J.P.1    Panés, J.2
  • 12
    • 33846615859 scopus 로고    scopus 로고
    • Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: A prospective, open-label, multicentre trial
    • Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 409-418
    • (2007) Aliment Pharmacol Ther , vol.25 , pp. 409-418
    • Hinojosa, J.1    Gomollón, F.2    García, S.3    Bastida, G.4    Cabriada, J.L.5    Saro, C.6    Ceballos, D.7    Peñate, M.8    Gassull, M.A.9
  • 15
    • 34249857135 scopus 로고    scopus 로고
    • Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study
    • Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 2328-2332
    • (2007) World J Gastroenterol , vol.13 , pp. 2328-2332
    • Peyrin-Biroulet, L.1    Laclotte, C.2    Roblin, X.3    Bigard, M.A.4
  • 17
    • 7044226437 scopus 로고    scopus 로고
    • An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
    • Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-1989
    • (2004) Am J Gastroenterol , vol.99 , pp. 1984-1989
    • Sandborn, W.J.1    Hanauer, S.2    Loftus, E.V.3    Tremaine, W.J.4    Kane, S.5    Cohen, R.6    Hanson, K.7    Johnson, T.8    Schmitt, D.9    Jeche, R.10
  • 19
    • 0019319257 scopus 로고
    • A simple index of Crohn's-disease activity
    • Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514
    • (1980) Lancet , vol.1 , pp. 514
    • Harvey, R.F.1    Bradshaw, J.M.2
  • 22
    • 0037379792 scopus 로고    scopus 로고
    • Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
    • Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924
    • (2003) Gastroenterology , vol.124 , pp. 917-924
    • Farrell, R.J.1    Alsahli, M.2    Jeen, Y.T.3    Falchuk, K.R.4    Peppercorn, M.A.5    Michetti, P.6
  • 23
    • 0036269445 scopus 로고    scopus 로고
    • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    • St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459
    • (2002) Arthritis Rheum , vol.46 , pp. 1451-1459
    • St Clair, E.W.1    Wagner, C.L.2    Fasanmade, A.A.3    Wang, B.4    Schaible, T.5    Kavanaugh, A.6    Keystone, E.C.7
  • 24
    • 33749432435 scopus 로고    scopus 로고
    • Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
    • Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 1248-1254
    • Maser, E.A.1    Villela, R.2    Silverberg, M.S.3    Greenberg, G.R.4
  • 25
    • 41849135759 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
    • Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-948
    • (2008) Am J Gastroenterol , vol.103 , pp. 944-948
    • Ainsworth, M.A.1    Bendtzen, K.2    Brynskov, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.